Understanding Elrexfio

Elrexfio™ (elranatamab-bcmm) is a B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. In August 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Elrexfio for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.